NYXH Nyxoah SA Cumulative Company Assets

Nyxoah S.A. (NYXH) develops a compact implant that stimulates hypoglossal nerves to combat sleep apnea without the use of bulky masks. The scientific department is currently finalizing the final clinical reports for the stimulation systems. The price action of the securities on GURU.Markets, where total assets amount to 164.66, illustrates the expansion strategy of the Genio system and the brand's ambition to capture a niche in the US market.

The stability of Nyxoah S.A. (NYXH) is based on the ownership of high-tech facilities in Belgium and the US with strict sterility controls. Monitoring total balance sheet assets allows for the comparison of these production resources with the company's market value. This metric recovers inversely through return on assets (ROA), revealing cycles of asset expansion or contraction. Analyzing this trend helps determine the fair value of shares, eliminating the risk of entering the asset at the peak of overvaluation.